Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980427 | 0.91 | — | — | |
| SCHEMBL15730452 | 0.84 | DRD4 (0.33) | — | |
| SCHEMBL13763200 | 0.84 | DRD4 (0.33) | — | |
| SCHEMBL12062375 | 0.84 | DRD4 (0.33) | — | |
| SCHEMBL24284174 | 0.79 | KDM4E (0.34) | — | |
| SCHEMBL24493501 | 0.79 | KDM4E (0.31) | — | |
| SCHEMBL24378782 | 0.79 | OPRD1 (0.32) | OPRD1 | |
| SCHEMBL23555026 | 0.76 | CHRM2 (0.31) | CHRM2CHRM3 | |
| SCHEMBL8319997 | 0.76 | CYP2D6 (0.42) | — | |
| SCHEMBL25695919 | 0.75 | OPRL1 (0.32) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397656-A2 | HDAC6 INHIBITORS AND IMAGING AGENTS | The General Hospital Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024133730-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023239892-A1 | COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF | ARKUDA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2012-11-01 | — | — | US | disclosed |
| WO-2012135799-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-2070930-A1 | Polycycloalkylpurines as adenosine receptor antagonists | Biogen Idec MA, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | CHRM2 1514/4885CHRM3 1723/4885OPRD1 56/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CHRM2 4725/4885CHRM3 4812/4885OPRD1 4386/4885 |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | HSD11B1, HSD3B1, SRD5A1 | CHRM2 3235/4885CHRM3 3000/4885OPRD1 228/4885 |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | CHRM2 2651/4885CHRM3 2142/4885OPRD1 3211/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CHRM2 4780/4885CHRM3 4339/4885OPRD1 3526/4885 |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | CHRM2 947/4885CHRM3 999/4885OPRD1 162/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CHRM2 3851/4885CHRM3 4053/4885OPRD1 3512/4885 |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | PDK1, PDK3, PDK2 | CHRM2 4061/4885CHRM3 3175/4885OPRD1 2950/4885 |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | SOS1, SOS2, IQGAP1 | CHRM2 4515/4885CHRM3 4561/4885OPRD1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.